Vaccines against Lassa virus diseases

Basic Information

Vaccines have contributed enormously to the successful control and elimination of many diseases, but few vaccines have so far been developed for the prevention and control of emerging infectious diseases. Lassa virus (LASV) has been added to the WHO R&D Blueprint list of diseases for which there is an urgent need for accelerated research and development, considering the disease’s potential to cause a public health emergency, and given the absence of efficacious drugs and/or vaccines. In the coming years, several candidate vaccines against LASV will enter clinical development and there is an urgent need to fast track their development. The aim is to facilitate the development of promising vaccines and the preparation of investigational sites in affected countries to be ready to perform proof of concept and/or pivotal efficacy trials.

Network EDCTP2
Aim of the joint call The purpose of this call for proposals is to support distinct strategic actions (clinical research activities) which are part of efforts to prepare and conduct a large-scale clinical trial that has the potential to achieve proof of concept and/or the demonstration of pivotal efficacy of novel candidate vaccines against LASV.
Type of joint call One Stage - Call with no pre-proposals submission
Launch date 02/11/2019
Deadline Full-Proposal 07/05/2020 Submitted proposal: n/a
Evaluation End Date n/a Successful proposal: n/a Proposals funded: n/a
Is call co-funded? No
Call follow up funding n/a
Call reasons n/a
Research fields
  • Health
Type of research n/a
Target groups n/a
Participating networks n/a

Organisations Participating

No participating organisations found.